ALSO READHalf of cancer drugs approved in UK show no survival benefits Scientists offer a ray of hope for patients with rare bone cancer patients South Asian women in UK hiding cancer due to stigma: Report Kulsoom Nawaz undergoes 2nd surgery for throat cancer in UK Kulsoom Nawaz undergoes 3rd comprehensive cancer surgery in UK
The findings could pave the way to identifying patients who are most at risk of their disease returning, and who might benefit from new immunotherapy treatments.
The research, which was led by researchers based at the Cancer Research UK Manchester Institute and The Christie NHS Foundation Trust, studied blood samples taken after surgery from 161 patients with stage 2 and 3 melanoma.
They then looked for faults in two genes that are linked to 70 percent of melanoma skin cancers - BRAF and NRAS.
After five years, 33 percent of patients who had a positive blood test for faults in either of the two genes were alive, compared to 65 percent of those who did not.
Lead author Richard Marais from the University of Manchester said, "For some patients with advanced melanoma, their cancer will eventually return. We have no accurate tests to predict who these patients will be, so our findings are really encouraging."
"If we can use this tumour DNA test to accurately predict if cancer is going to come back, then it could help doctors decide which patients could benefit from new immunotherapies," Marais added.
These treatments can then reduce the risk of the cancer spreading.
The research appears in the Annals of Oncology journal.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)